{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:59:14Z","timestamp":1787068754396,"version":"build-2736575974"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T00:00:00Z","timestamp":1588550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T00:00:00Z","timestamp":1588550400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cerebrospinal fluid (CSF) A\u03b242 and tau protein levels are established diagnostic biomarkers of Alzheimer\u2019s disease (AD). However, their inadequacy to represent clinical efficacy in drug trials indicates the need for new biomarkers. Sequential window acquisition of all theoretical fragment ion spectra (SWATH)-based mass spectrometry (MS) is an advanced proteomic tool for large-scale, high-quality quantification. In this study, SWATH-MS showed that VGF, chromogranin-A, secretogranin-1, and opioid-binding protein\/cell adhesion molecule were significantly decreased in 42 AD patients compared to 39 controls, whereas 14-3-3\u03b6 was increased (FDR &lt; 0.05). In addition, 16 other proteins showed substantial changes (FDR &lt; 0.2). The expressions of the top 21 analytes were closely interconnected, but were poorly correlated with CSF A\u03b242, tTau, and pTau181 levels. Logistic regression analysis and data mining were used to establish the best algorithm for AD, which created novel biomarker panels with high diagnostic value (AUC = 0.889 and 0.924) and a strong correlation with clinical severity (all p &lt; 0.001). Targeted proteomics was used to validate their usefulness in a different cohort (n = 36) that included patients with other brain disorders (all p &lt; 0.05). This study provides a list of proteins (and combinations thereof) that could serve as new AD biomarkers.<\/jats:p>","DOI":"10.1038\/s41598-020-64461-y","type":"journal-article","created":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T06:05:01Z","timestamp":1588572301000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["SWATH-MS analysis of cerebrospinal fluid to generate a robust battery of biomarkers for Alzheimer\u2019s disease"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3027-3259","authenticated-orcid":false,"given":"Sun Ah","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Myung","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Sung","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Ho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bumhee","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung Jun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong-Ho","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Seok","family":"Chae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee Hyang","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4180-8626","authenticated-orcid":false,"given":"Seong Hye","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Je-Hyun","family":"Baek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,4]]},"reference":[{"key":"64461_CR1","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/ana.21610","volume":"65","author":"LM Shaw","year":"2009","unstructured":"Shaw, L. M. et al. Cerebrospinal fluid biomarker signature in Alzheimer\u2019s disease neuroimaging initiative subjects. Ann. Neurol. 65, 403\u2013413, https:\/\/doi.org\/10.1002\/ana.21610 (2009).","journal-title":"Ann. Neurol."},{"key":"64461_CR2","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann, G. M. et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 7, 263\u2013269, https:\/\/doi.org\/10.1016\/j.jalz.2011.03.005 (2011).","journal-title":"Alzheimers Dement."},{"key":"64461_CR3","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr.","year":"2018","unstructured":"Jack, C. R. Jr. et al. NIA-AA Research Framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 14, 535\u2013562, https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018 (2018).","journal-title":"Alzheimers Dement."},{"key":"64461_CR4","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1038\/nm.2221","volume":"16","author":"K Blennow","year":"2010","unstructured":"Blennow, K. Biomarkers in Alzheimer\u2019s disease drug development. Nat. Med. 16, 1218\u20131222, https:\/\/doi.org\/10.1038\/nm.2221 (2010).","journal-title":"Nat. Med."},{"key":"64461_CR5","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1202753","volume":"367","author":"RJ Bateman","year":"2012","unstructured":"Bateman, R. J. et al. Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease. N. Engl. J. Med. 367, 795\u2013804, https:\/\/doi.org\/10.1056\/NEJMoa1202753 (2012).","journal-title":"N. Engl. J. Med."},{"key":"64461_CR6","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.dadm.2015.09.001","volume":"1","author":"N Mattsson","year":"2015","unstructured":"Mattsson, N. et al. Revolutionizing Alzheimer\u2019s disease and clinical trials through biomarkers. Alzheimers Dement. (Amst.) 1, 412\u2013419, https:\/\/doi.org\/10.1016\/j.dadm.2015.09.001 (2015).","journal-title":"Alzheimers Dement. (Amst.)"},{"key":"64461_CR7","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s00401-018-1932-x","volume":"136","author":"JL Molinuevo","year":"2018","unstructured":"Molinuevo, J. L. et al. Current state of Alzheimer\u2019s fluid biomarkers. Acta Neuropathol. 136, 821\u2013853, https:\/\/doi.org\/10.1007\/s00401-018-1932-x (2018).","journal-title":"Acta Neuropathol."},{"key":"64461_CR8","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1080\/14789450.2017.1384697","volume":"14","author":"E Portelius","year":"2017","unstructured":"Portelius, E. et al. Proteomic studies of cerebrospinal fluid biomarkers of Alzheimer\u2019s disease: an update. Expert Rev. Proteomics 14, 1007\u20131020, https:\/\/doi.org\/10.1080\/14789450.2017.1384697 (2017).","journal-title":"Expert Rev. Proteomics"},{"key":"64461_CR9","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1080\/14789450.2017.1322904","volume":"14","author":"JG Meyer","year":"2017","unstructured":"Meyer, J. G. & Schilling, B. Clinical applications of quantitative proteomics using targeted and untargeted data-independent acquisition techniques. Expert Rev. Proteomics 14, 419\u2013429, https:\/\/doi.org\/10.1080\/14789450.2017.1322904 (2017).","journal-title":"Expert Rev. Proteomics"},{"key":"64461_CR10","doi-asserted-by":"publisher","first-page":"e8126","DOI":"10.15252\/msb.20178126","volume":"14","author":"C Ludwig","year":"2018","unstructured":"Ludwig, C. et al. Data-independent acquisition-based SWATH-MS for quantitative proteomics: a tutorial. Mol. Syst. Biol. 14, e8126, https:\/\/doi.org\/10.15252\/msb.20178126 (2018).","journal-title":"Mol. Syst. Biol."},{"key":"64461_CR11","doi-asserted-by":"publisher","first-page":"239204","DOI":"10.4061\/2009\/239204","volume":"2009","author":"K Chandramouli","year":"2009","unstructured":"Chandramouli, K. & Qian, P. Y. Proteomics: challenges, techniques and possibilities to overcome biological sample complexity. Hum. Genomics Proteomics 2009, 239204, https:\/\/doi.org\/10.4061\/2009\/239204 (2009).","journal-title":"Hum. Genomics Proteomics"},{"key":"64461_CR12","doi-asserted-by":"publisher","first-page":"O111.016717","DOI":"10.1074\/mcp.O111.016717","volume":"11","author":"LC Gillet","year":"2012","unstructured":"Gillet, L. C. et al. Targeted data extraction of the MS\/MS spectra generated by data-independent acquisition: a new concept for consistent and accurate proteome analysis. Mol. Cell. Proteomics 11, O111.016717, https:\/\/doi.org\/10.1074\/mcp.O111.016717 (2012).","journal-title":"Mol. Cell. Proteomics"},{"key":"64461_CR13","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12014-018-9201-5","volume":"15","author":"A Jylha","year":"2018","unstructured":"Jylha, A. et al. Comparison of iTRAQ and SWATH in a clinical study with multiple time points. Clin. Proteomics 15, 24, https:\/\/doi.org\/10.1186\/s12014-018-9201-5 (2018).","journal-title":"Clin. Proteomics"},{"key":"64461_CR14","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/wad.0000000000000184","volume":"31","author":"SA Park","year":"2017","unstructured":"Park, S. A. et al. Cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease in South Korea. Alzheimer Dis. Assoc. Disord. 31, 13\u201318, https:\/\/doi.org\/10.1097\/wad.0000000000000184 (2017).","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"64461_CR15","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B Methodol. 57, 289\u2013300 (1995).","journal-title":"J. R. Stat. Soc. Ser. B Methodol."},{"key":"64461_CR16","doi-asserted-by":"publisher","first-page":"M110.004374","DOI":"10.1074\/mcp.M110.004374","volume":"10","author":"AP Diz","year":"2011","unstructured":"Diz, A. P., Carvajal-Rodriguez, A. & Skibinski, D. O. Multiple hypothesis testing in proteomics: a strategy for experimental work. Mol. Cell. Proteomics 10, M110.004374, https:\/\/doi.org\/10.1074\/mcp.M110.004374 (2011).","journal-title":"Mol. Cell. Proteomics"},{"key":"64461_CR17","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1093\/bib\/bbs034","volume":"14","author":"WG Touw","year":"2013","unstructured":"Touw, W. G. et al. Data mining in the Life Sciences with Random Forest: a walk in the park or lost in the jungle? Brief Bioinform 14, 315\u2013326, https:\/\/doi.org\/10.1093\/bib\/bbs034 (2013).","journal-title":"Brief Bioinform"},{"key":"64461_CR18","doi-asserted-by":"publisher","first-page":"3999","DOI":"10.1007\/s12035-017-0609-0","volume":"55","author":"S Yu","year":"2018","unstructured":"Yu, S. et al. Serum Protein-Based Profiles as Novel Biomarkers for the Diagnosis of Alzheimer\u2019s Disease. Mol. Neurobiol. 55, 3999\u20134008, https:\/\/doi.org\/10.1007\/s12035-017-0609-0 (2018).","journal-title":"Mol. Neurobiol."},{"key":"64461_CR19","doi-asserted-by":"publisher","first-page":"10800","DOI":"10.1523\/JNEUROSCI.23-34-10800.2003","volume":"23","author":"J Alder","year":"2003","unstructured":"Alder, J. et al. Brain-derived neurotrophic factor-induced gene expression reveals novel actions of VGF in hippocampal synaptic plasticity. J. Neurosci. 23, 10800\u201310808 (2003).","journal-title":"J. Neurosci."},{"key":"64461_CR20","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1006\/mcne.1995.1015","volume":"6","author":"A Bonni","year":"1995","unstructured":"Bonni, A., Ginty, D. D., Dudek, H. & Greenberg, M. E. Serine 133-phosphorylated CREB induces transcription via a cooperative mechanism that may confer specificity to neurotrophin signals. Mol. Cell. Neurosci. 6, 168\u2013183, https:\/\/doi.org\/10.1006\/mcne.1995.1015 (1995).","journal-title":"Mol. Cell. Neurosci."},{"key":"64461_CR21","doi-asserted-by":"publisher","first-page":"3815","DOI":"10.1073\/pnas.89.9.3815","volume":"89","author":"R Possenti","year":"1992","unstructured":"Possenti, R., Di Rocco, G., Nasi, S. & Levi, A. Regulatory elements in the promoter region of vgf, a nerve growth factor-inducible gene. Proc. Natl. Acad. Sci. USA 89, 3815\u20133819, https:\/\/doi.org\/10.1073\/pnas.89.9.3815 (1992).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"64461_CR22","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1210\/er.2010-0027","volume":"32","author":"A Bartolomucci","year":"2011","unstructured":"Bartolomucci, A. et al. The extended granin family: structure, function, and biomedical implications. Endocr. Rev. 32, 755\u2013797, https:\/\/doi.org\/10.1210\/er.2010-0027 (2011).","journal-title":"Endocr. Rev."},{"key":"64461_CR23","doi-asserted-by":"publisher","first-page":"e16032","DOI":"10.1371\/journal.pone.0016032","volume":"6","author":"RJ Perrin","year":"2011","unstructured":"Perrin, R. J. et al. Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer\u2019s disease. PLoS One 6, e16032, https:\/\/doi.org\/10.1371\/journal.pone.0016032 (2011).","journal-title":"PLoS One"},{"key":"64461_CR24","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1002\/pmic.200300470","volume":"3","author":"O Carrette","year":"2003","unstructured":"Carrette, O. et al. A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer\u2019s disease. Proteomics 3, 1486\u20131494, https:\/\/doi.org\/10.1002\/pmic.200300470 (2003).","journal-title":"Proteomics"},{"key":"64461_CR25","doi-asserted-by":"publisher","first-page":"e26540","DOI":"10.1371\/journal.pone.0026540","volume":"6","author":"H Jahn","year":"2011","unstructured":"Jahn, H. et al. Peptide fingerprinting of Alzheimer\u2019s disease in cerebrospinal fluid: identification and prospective evaluation of new synaptic biomarkers. PLoS One 6, e26540, https:\/\/doi.org\/10.1371\/journal.pone.0026540 (2011).","journal-title":"PLoS One"},{"key":"64461_CR26","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13195-017-0335-x","volume":"10","author":"FH Duits","year":"2018","unstructured":"Duits, F. H. et al. Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer\u2019s disease. Alzheimers Res. Ther. 10, 5, https:\/\/doi.org\/10.1186\/s13195-017-0335-x (2018).","journal-title":"Alzheimers Res. Ther."},{"key":"64461_CR27","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/cns.13050","volume":"25","author":"S Merlo","year":"2019","unstructured":"Merlo, S., Spampinato, S. F. & Sortino, M. A. Early compensatory responses against neuronal injury: a new therapeutic window of opportunity for Alzheimer\u2019s disease? CNS Neurosci. Ther. 25, 5\u201313, https:\/\/doi.org\/10.1111\/cns.13050 (2019).","journal-title":"CNS Neurosci. Ther."},{"key":"64461_CR28","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1111\/j.1471-4159.2007.04985.x","volume":"103","author":"N Mattsson","year":"2007","unstructured":"Mattsson, N. et al. Cerebrospinal fluid concentrations of peptides derived from chromogranin B and secretogranin II are decreased in multiple sclerosis. J. Neurochem. 103, 1932\u20131939, https:\/\/doi.org\/10.1111\/j.1471-4159.2007.04985.x (2007).","journal-title":"J. Neurochem."},{"key":"64461_CR29","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/S0924-977X(98)00042-X","volume":"9","author":"M Landen","year":"1999","unstructured":"Landen, M. et al. Reduction of chromogranin A and B but not C in the cerebrospinal fluid in subjects with schizophrenia. Eur. Neuropsychopharmacol. 9, 311\u2013315 (1999).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"64461_CR30","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1111\/j.1469-7580.2010.01309.x","volume":"217","author":"C Cocco","year":"2010","unstructured":"Cocco, C. et al. Distribution of VGF peptides in the human cortex and their selective changes in Parkinson\u2019s and Alzheimer\u2019s diseases. J. Anat. 217, 683\u2013693, https:\/\/doi.org\/10.1111\/j.1469-7580.2010.01309.x (2010).","journal-title":"J. Anat."},{"key":"64461_CR31","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1212\/01.wnl.0000203129.82104.07","volume":"66","author":"GM Pasinetti","year":"2006","unstructured":"Pasinetti, G. M. et al. Identification of potential CSF biomarkers in ALS. Neurology 66, 1218\u20131222, https:\/\/doi.org\/10.1212\/01.wnl.0000203129.82104.07 (2006).","journal-title":"Neurology"},{"key":"64461_CR32","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/ane.12735","volume":"136","author":"M Kaiserova","year":"2017","unstructured":"Kaiserova, M. et al. Cerebrospinal fluid levels of chromogranin A and phosphorylated neurofilament heavy chain are elevated in amyotrophic lateral sclerosis. Acta Neurol. Scand. 136, 360\u2013364, https:\/\/doi.org\/10.1111\/ane.12735 (2017).","journal-title":"Acta Neurol. Scand."},{"key":"64461_CR33","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/00005072-199203000-00003","volume":"51","author":"D Leifer","year":"1992","unstructured":"Leifer, D. & Kowall, N. W. Thy-1 in hippocampus: normal anatomy and neuritic growth in Alzheimer\u2019s disease. J. Neuropathol. Exp. Neurol. 51, 133\u2013141 (1992).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"64461_CR34","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.neuroscience.2016.05.050","volume":"330","author":"L Liu","year":"2016","unstructured":"Liu, L., Watanabe, N., Akatsu, H. & Nishimura, M. Neuronal expression of ILEI\/FAM3C and its reduction in Alzheimer\u2019s disease. Neuroscience 330, 236\u2013246, https:\/\/doi.org\/10.1016\/j.neuroscience.2016.05.050 (2016).","journal-title":"Neuroscience"},{"key":"64461_CR35","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/j.1750-3639.2012.00644.x","volume":"23","author":"V Pla","year":"2013","unstructured":"Pla, V. et al. Secretory sorting receptors carboxypeptidase E and secretogranin III in amyloid beta-associated neural degeneration in Alzheimer\u2019s disease. Brain Pathol. 23, 274\u2013284, https:\/\/doi.org\/10.1111\/j.1750-3639.2012.00644.x (2013).","journal-title":"Brain Pathol."},{"key":"64461_CR36","doi-asserted-by":"publisher","first-page":"3420","DOI":"10.1523\/jneurosci.3630-14.2015","volume":"35","author":"CA Puddifoot","year":"2015","unstructured":"Puddifoot, C. A., Wu, M., Sung, R. J. & Joiner, W. J. Ly6h regulates trafficking of alpha7 nicotinic acetylcholine receptors and nicotine-induced potentiation of glutamatergic signaling. J. Neurosci. 35, 3420\u20133430, https:\/\/doi.org\/10.1523\/jneurosci.3630-14.2015 (2015).","journal-title":"J. Neurosci."},{"key":"64461_CR37","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.mcn.2011.12.002","volume":"49","author":"T Sakurai","year":"2012","unstructured":"Sakurai, T. The role of NrCAM in neural development and disorders-beyond a simple glue in the brain. Mol. Cell. Neurosci. 49, 351\u2013363, https:\/\/doi.org\/10.1016\/j.mcn.2011.12.002 (2012).","journal-title":"Mol. Cell. Neurosci."},{"key":"64461_CR38","doi-asserted-by":"publisher","first-page":"5345","DOI":"10.1523\/jneurosci.1875-16.2017","volume":"37","author":"S Schilling","year":"2017","unstructured":"Schilling, S. et al. APLP1 Is a synaptic cell adhesion molecule, supporting maintenance of dendritic spines and basal synaptic transmission. J. Neurosci. 37, 5345\u20135365, https:\/\/doi.org\/10.1523\/jneurosci.1875-16.2017 (2017).","journal-title":"J. Neurosci."},{"key":"64461_CR39","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/prca.201400178","volume":"9","author":"DS Spellman","year":"2015","unstructured":"Spellman, D. S. et al. Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI) CSF. Proteomics Clin. Appl. 9, 715\u2013731, https:\/\/doi.org\/10.1002\/prca.201400178 (2015).","journal-title":"Proteomics Clin. Appl."},{"key":"64461_CR40","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1038\/nrn1197","volume":"4","author":"D Berg","year":"2003","unstructured":"Berg, D., Holzmann, C. & Riess, O. 14-3-3 proteins in the nervous system. Nat. Rev. Neurosci. 4, 752\u2013762, https:\/\/doi.org\/10.1038\/nrn1197 (2003).","journal-title":"Nat. Rev. Neurosci."},{"key":"64461_CR41","doi-asserted-by":"publisher","first-page":"25247","DOI":"10.1074\/jbc.M003738200","volume":"275","author":"M Hashiguchi","year":"2000","unstructured":"Hashiguchi, M., Sobue, K. & Paudel, H. K. 14-3-3zeta is an effector of tau protein phosphorylation. J. Biol. Chem. 275, 25247\u201325254, https:\/\/doi.org\/10.1074\/jbc.M003738200 (2000).","journal-title":"J. Biol. Chem."},{"key":"64461_CR42","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/j.1471-4159.2008.05716.x","volume":"108","author":"G Sadik","year":"2009","unstructured":"Sadik, G. et al. Phosphorylation of tau at Ser214 mediates its interaction with 14-3-3 protein: implications for the mechanism of tau aggregation. J. Neurochem. 108, 33\u201343, https:\/\/doi.org\/10.1111\/j.1471-4159.2008.05716.x (2009).","journal-title":"J. Neurochem."},{"key":"64461_CR43","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1021\/pr3001546","volume":"11","author":"VP Andreev","year":"2012","unstructured":"Andreev, V. P. et al. Label-free quantitative LC-MS proteomics of Alzheimer\u2019s disease and normally aged human brains. J. Proteome Res. 11, 3053\u20133067, https:\/\/doi.org\/10.1021\/pr3001546 (2012).","journal-title":"J. Proteome Res."},{"key":"64461_CR44","doi-asserted-by":"publisher","first-page":"615745","DOI":"10.1155\/2013\/615745","volume":"2013","author":"Y Sun","year":"2013","unstructured":"Sun, Y. et al. Elevated osteopontin levels in mild cognitive impairment and Alzheimer\u2019s disease. Mediators Inflamm. 2013, 615745, https:\/\/doi.org\/10.1155\/2013\/615745 (2013).","journal-title":"Mediators Inflamm."},{"key":"64461_CR45","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13024-015-0059-y","volume":"10","author":"WE Heywood","year":"2015","unstructured":"Heywood, W. E. et al. Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay. Mol. Neurodegener. 10, 64, https:\/\/doi.org\/10.1186\/s13024-015-0059-y (2015).","journal-title":"Mol. Neurodegener."},{"key":"64461_CR46","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1159\/000090631","volume":"21","author":"AK Wallin","year":"2006","unstructured":"Wallin, A. K. et al. CSF biomarkers for Alzheimer\u2019s Disease: levels of beta-amyloid, tau, phosphorylated tau relate to clinical symptoms and survival. Dement. Geriatr. Cogn. Disord. 21, 131\u2013138, https:\/\/doi.org\/10.1159\/000090631 (2006).","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"64461_CR47","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1001\/jama.2009.1064","volume":"302","author":"N Mattsson","year":"2009","unstructured":"Mattsson, N. et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302, 385\u2013393, https:\/\/doi.org\/10.1001\/jama.2009.1064 (2009).","journal-title":"JAMA"},{"key":"64461_CR48","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1212\/WNL.0b013e3181af79e5","volume":"73","author":"P Vemuri","year":"2009","unstructured":"Vemuri, P. et al. MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology 73, 287\u2013293, https:\/\/doi.org\/10.1212\/WNL.0b013e3181af79e5 (2009).","journal-title":"Neurology"},{"key":"64461_CR49","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1373\/clinchem.2009.130518","volume":"56","author":"C Mulder","year":"2010","unstructured":"Mulder, C. et al. Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin. Chem. 56, 248\u2013253, https:\/\/doi.org\/10.1373\/clinchem.2009.130518 (2010).","journal-title":"Clin. Chem."},{"key":"64461_CR50","doi-asserted-by":"publisher","unstructured":"Jung, N.Y. et al. Comparison of diagnostic performances between cerebrospinal fluid biomarkers and amyloid PET in a clinical setting. J. Alzheimers Dis. 10.3233\/JAD-191109, https:\/\/doi.org\/10.3233\/JAD-191109 (2020).","DOI":"10.3233\/JAD-191109"},{"key":"64461_CR51","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.jalz.2011.09.224","volume":"8","author":"M Farlow","year":"2012","unstructured":"Farlow, M. et al. Safety and biomarker effects of solanezumab in patients with Alzheimer\u2019s disease. Alzheimers Dement. 8, 261\u2013271, https:\/\/doi.org\/10.1016\/j.jalz.2011.09.224 (2012).","journal-title":"Alzheimers Dement."},{"key":"64461_CR52","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/s1474-4422(10)70043-0","volume":"9","author":"JO Rinne","year":"2010","unstructured":"Rinne, J. O. et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer\u2019s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 9, 363\u2013372, https:\/\/doi.org\/10.1016\/s1474-4422(10)70043-0 (2010).","journal-title":"Lancet Neurol."},{"key":"64461_CR53","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1007\/s00018-019-03040-5","volume":"76","author":"K Dhiman","year":"2019","unstructured":"Dhiman, K., Blennow, K., Zetterberg, H., Martins, R. N. & Gupta, V. B. Cerebrospinal fluid biomarkers for understanding multiple aspects of Alzheimer\u2019s disease pathogenesis. Cell. Mol. Life Sci. 76, 1833\u20131863, https:\/\/doi.org\/10.1007\/s00018-019-03040-5 (2019).","journal-title":"Cell. Mol. Life Sci."},{"key":"64461_CR54","doi-asserted-by":"publisher","first-page":"661","DOI":"10.3233\/jad-141011","volume":"44","author":"HK Park","year":"2015","unstructured":"Park, H. K. et al. Cognitive profiles and neuropsychiatric symptoms in Korean early-onset Alzheimer\u2019s disease patients: a CREDOS study. J. Alzheimers Dis. 44, 661\u2013673, https:\/\/doi.org\/10.3233\/jad-141011 (2015).","journal-title":"J. Alzheimers Dis."},{"key":"64461_CR55","doi-asserted-by":"publisher","first-page":"132","DOI":"10.3988\/jcn.2015.11.2.132","volume":"11","author":"SA Park","year":"2015","unstructured":"Park, S. A. et al. A consensus in Korea regarding a protocol to reduce preanalytical sources of variability in the measurement of the cerebrospinal fluid biomarkers of Alzheimer\u2019s disease. J. Clin. Neurol. 11, 132\u2013141, https:\/\/doi.org\/10.3988\/jcn.2015.11.2.132 (2015).","journal-title":"J. Clin. Neurol."},{"key":"64461_CR56","doi-asserted-by":"publisher","first-page":"933","DOI":"10.5012\/bkcs.2014.35.3.933","volume":"35","author":"WK Lee","year":"2014","unstructured":"Lee, W. K., Baek, J. H., Ryoo, S. W. & Yu, Y. G. Swath-based comparative proteomic analysis of the Mycobacterium bovis BCG-Korea strain. Bull. Korean Chem. Soc. 35, 933\u2013937, https:\/\/doi.org\/10.5012\/bkcs.2014.35.3.933 (2014).","journal-title":"Bull. Korean Chem. Soc."},{"key":"64461_CR57","doi-asserted-by":"publisher","first-page":"46177","DOI":"10.18632\/oncotarget.17579","volume":"8","author":"F Spreafico","year":"2017","unstructured":"Spreafico, F. et al. Proteomic analysis of cerebrospinal fluid from children with central nervous system tumors identifies candidate proteins relating to tumor metastatic spread. Oncotarget 8, 46177\u201346190, https:\/\/doi.org\/10.18632\/oncotarget.17579 (2017).","journal-title":"Oncotarget"},{"key":"64461_CR58","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1093\/bioinformatics\/btq054","volume":"26","author":"B MacLean","year":"2010","unstructured":"MacLean, B. et al. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics 26, 966\u2013968, https:\/\/doi.org\/10.1093\/bioinformatics\/btq054 (2010).","journal-title":"Bioinformatics"},{"key":"64461_CR59","doi-asserted-by":"publisher","first-page":"4118","DOI":"10.1021\/acs.jproteome.5b00183","volume":"14","author":"A Pursiheimo","year":"2015","unstructured":"Pursiheimo, A. et al. Optimization of statistical methods impact on quantitative proteomics data. J Proteome Res 14, 4118\u20134126, https:\/\/doi.org\/10.1021\/acs.jproteome.5b00183 (2015).","journal-title":"J Proteome Res"},{"key":"64461_CR60","doi-asserted-by":"publisher","first-page":"W90","DOI":"10.1093\/nar\/gkw377","volume":"44","author":"MV Kuleshov","year":"2016","unstructured":"Kuleshov, M. V. et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 44, W90\u201397, https:\/\/doi.org\/10.1093\/nar\/gkw377 (2016).","journal-title":"Nucleic Acids Res."},{"key":"64461_CR61","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1136\/jnnp.55.10.967","volume":"55","author":"P Scheltens","year":"1992","unstructured":"Scheltens, P. et al. Atrophy of medial temporal lobes on MRI in \u201cprobable\u201d Alzheimer\u2019s disease and normal ageing: diagnostic value and neuropsychological correlates. J. Neurol. Neurosurg. Psychiatry 55, 967\u2013972, https:\/\/doi.org\/10.1136\/jnnp.55.10.967 (1992).","journal-title":"J. Neurol. Neurosurg. Psychiatry"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-64461-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-64461-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-64461-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T00:40:17Z","timestamp":1722818417000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-64461-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,4]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["64461"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-64461-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,4]]},"assertion":[{"value":"13 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7423"}}